Physician profile
Pavan G Reddy
NPI 1659329084
$953.23
in general payments reported to CMS, 2019-2025
11 companies · $196 in 2025
The $196 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.77 · 2020: $235 · 2021: $22.51 · 2022: $21.91 · 2023: $30.98 · 2024: $393 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $620.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $345.27 | 2020-2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $189.13 | 2023-2024 | Iclusig, Hyqvia |
| Abbott Laboratories | $177.50 | 2024 | Mitraclip |
| Acclarent, INC | $64.16 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $48.99 | 2025 | Dupixent |
| Pharming Healthcare, INC. | $27.91 | 2025 | Ruconest |
| Genzyme Corporation | $24.23 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $24.19 | 2025 | Tezspire |
| Glaxosmithkline, LLC. | $19.83 | 2019 | |
| Genentech USA, INC. | $17.82 | 2024 | Xolair |
| E.R. Squibb & Sons, L.L.C. | $14.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pavan Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.